Spots Global Cancer Trial Database for erk
Every month we try and update this database with for erk cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Study of ASTX029 in Subjects With Advanced Solid Tumors | NCT03520075 | Solid Tumor, Ad... | ASTX029 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | NCT02711345 | Ovarian Neoplas... Non-Small-Cell ... Melanoma Other Solid Tum... | LTT462 | 12 Years - | Novartis | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | NCT04916236 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... KRAS Mutation-R... | RMC-4630 LY3214996 | 18 Years - | The Netherlands Cancer Institute | |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | NCT04916236 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... KRAS Mutation-R... | RMC-4630 LY3214996 | 18 Years - | The Netherlands Cancer Institute | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | NCT05279859 | Acute Myeloid L... | ERAS-007 ERAS-601 Gilteritinib | 18 Years - 99 Years | Erasca, Inc. | |
| Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | NCT01709292 | Thyroid Cancer | Vemurafenib (Al... Vemurafenib (Po... Post Surgery - ... | 18 Years - | M.D. Anderson Cancer Center | |
| Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | NCT01709292 | Thyroid Cancer | Vemurafenib (Al... Vemurafenib (Po... Post Surgery - ... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | NCT04959981 | Advanced Non-sq... | ERAS-007 ERAS-601 Osimertinib Sotorasib | 18 Years - 99 Years | Erasca, Inc. | |
| LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy | NCT04081259 | Acute Myeloid L... | LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Study of ASTX029 in Subjects With Advanced Solid Tumors | NCT03520075 | Solid Tumor, Ad... | ASTX029 | 18 Years - | Astex Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
